skip to main content
Idioma:

COVID-19 VACCINE SAFETY DURING PREGNANCY AND BREASTFEEDING IN WOMEN WITH AUTOIMMUNE DISEASES: RESULTS FROM THE COVAD STUDY

Andreoli, L. ; Lini, D. ; Schreiber, K. ; Sen, P. ; Ravichandran, N. ; Parodis, Ioannis ; Toro Gutierrez, C. E. ; Katchamart, W. ; Goo, P. A. ; Shumnalieva, R. ; Chibuzo, O. C. ; Velikova, T. ; Day, J. ; Joshi, M. ; Katsuyuki Shinjo, S. ; Gracia-Ramos, A. E. ; Cavagna, L. ; Kuwana, M. ; Knitza, J. ; Makol, A. ; Chen, Y. M. ; Chinoy, H. ; Agarwal, V. ; Aggarwal, R. ; Gupta, L.

ANNALS OF THE RHEUMATIC DISEASES, 2023, Vol.82 (Suppl. 1), p.56 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    COVID-19 VACCINE SAFETY DURING PREGNANCY AND BREASTFEEDING IN WOMEN WITH AUTOIMMUNE DISEASES: RESULTS FROM THE COVAD STUDY
  • Autor: Andreoli, L. ; Lini, D. ; Schreiber, K. ; Sen, P. ; Ravichandran, N. ; Parodis, Ioannis ; Toro Gutierrez, C. E. ; Katchamart, W. ; Goo, P. A. ; Shumnalieva, R. ; Chibuzo, O. C. ; Velikova, T. ; Day, J. ; Joshi, M. ; Katsuyuki Shinjo, S. ; Gracia-Ramos, A. E. ; Cavagna, L. ; Kuwana, M. ; Knitza, J. ; Makol, A. ; Chen, Y. M. ; Chinoy, H. ; Agarwal, V. ; Aggarwal, R. ; Gupta, L.
  • Assuntos: COVID ; Medicin och hälsovetenskap ; Pregnancy and reproduction ; Vaccination/Immunization
  • É parte de: ANNALS OF THE RHEUMATIC DISEASES, 2023, Vol.82 (Suppl. 1), p.56
  • Descrição: Background : COVID-19 vaccine hesitancy among pregnant and breastfeeding women with autoimmune diseases (AID) is often attributed to the fear of adverse events (AE) and disease flares (DF). No data are available regarding COVID-19 vaccine safety in this population. Objectives : We aimed at describing delayed-onset (>7 days) vaccine-related AE (minor and major), DF, and related AID treatment modifications from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods : Among complete responses from 9201 participants as of June 21, 2022, 6787 (73.8%) were women. Six subgroups were identified upon diagnosis of AID vs healthy controls (HC) and their pregnancy/breastfeeding status at the time of any dose of vaccine (Figure 1). Results : Forty pregnant and 52 breastfeeding AID patients were identified and their vaccination rates (at least one dose) was 100% and 96.2%, respectively (Table 1). Overall AE, minor AE, and major AE were reported significantly more frequently by pregnant than non-pregnant patients (45% vs. 26%, p=0.01; 40% vs. 25.9%, p=0.03; 17.5% vs. 4.6%, p<0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC. Post-vaccination DF were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18% of age- and disease-matched control patients (n=2315). All DF in pregnant/breastfeeding patients were managed with glucocorticoids and a fifth of them required initiation or change in immunosuppressive treatment. Conclusion : This study provides the first insights into the safety of COVID-19 vaccination during the antenatal period in women with AID. While AEs were more commonly reported by pregnant patients with AID, these were no higher than among pregnant healthy controls without AID. These observations are reassuring, likely to strengthen physician-patient communication and overcome hesitancy as the benefits for the mother and fetus by passive immunization are likely to overweigh the potential risks of AE and DF. Reference : [1]Fazal ZZ, et al; COVAD Study Group. COVAD survey 2 long-term outcomes: unmet need and protocol. Rheumatol Int 2022; 42:2151-2158.
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.